Age-stratified outcomes of holmium laser enucleation of the prostate

Chinedu O. Mmeje, Rafael Nunez-Nateras, Jonathan N. Warner, Mitchell R Humphreys

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Objective To present the first age-stratified assessment of outcomes after holmium laser enucleation of the prostate (HoLEP) for the treatment of lower urinary tract symptoms resulting from prostate enlargement. Patients and Methods We retrospectively analysed and compared the morbidity, and the peri-operative and functional outcomes of patients aged 50-59, 60-69, 70-79 and ≥80 years. Complications at 30 days were stratified using the Clavien system. Functional outcomes were assessed using the International Prostate Symptom Score (IPSS), maximum urinary flow rate (Qmax), post-void residual urine volume (PVR) and urinary continence. Results A total of 311 patients underwent HoLEP for obstructive voiding symptoms from August 2007 to June 2011, of whom 22 patients were aged 50-59 years, 91 were aged 60-69 years, 153 were aged 70-79 years, and 45 were aged ≥80 years. The overall morbidity rates were similar among the age groups (20, 24.4, 21.6 and 22.1% for groups 1, 2, 3 and 4, respectively), as were the incidence of significant complications (Clavien grade ≥ III), change in serum haemoglobin level, and length of hospital stay. Patients ≥80 years did have a longer catheterization time (3.4 days) than patients aged 50-59 years (1.68 days). By 1 year there were no significant differences in urinary continence, IPSS, Qmax, or PVR among the age groups. Conclusions Overall morbidity, hospital stay, and 1-year functional outcomes of HoLEP were similar among all age groups. This study shows that HoLEP is a safe and effective treatment for benign prostatic hyperplasia regardless of age.

Original languageEnglish (US)
Pages (from-to)982-989
Number of pages8
JournalBJU International
Volume112
Issue number7
DOIs
StatePublished - Nov 2013

Fingerprint

Solid-State Lasers
Prostate
Length of Stay
Age Groups
Morbidity
Lower Urinary Tract Symptoms
Residual Volume
Prostatic Hyperplasia
Catheterization
Hemoglobins
Outcome Assessment (Health Care)
Urine
Incidence
Therapeutics
Serum

Keywords

  • BPH
  • enucleation
  • holmium
  • laser
  • prostate

ASJC Scopus subject areas

  • Urology

Cite this

Age-stratified outcomes of holmium laser enucleation of the prostate. / Mmeje, Chinedu O.; Nunez-Nateras, Rafael; Warner, Jonathan N.; Humphreys, Mitchell R.

In: BJU International, Vol. 112, No. 7, 11.2013, p. 982-989.

Research output: Contribution to journalArticle

Mmeje, Chinedu O. ; Nunez-Nateras, Rafael ; Warner, Jonathan N. ; Humphreys, Mitchell R. / Age-stratified outcomes of holmium laser enucleation of the prostate. In: BJU International. 2013 ; Vol. 112, No. 7. pp. 982-989.
@article{a5550e406e084a4d94c15531970bd41c,
title = "Age-stratified outcomes of holmium laser enucleation of the prostate",
abstract = "Objective To present the first age-stratified assessment of outcomes after holmium laser enucleation of the prostate (HoLEP) for the treatment of lower urinary tract symptoms resulting from prostate enlargement. Patients and Methods We retrospectively analysed and compared the morbidity, and the peri-operative and functional outcomes of patients aged 50-59, 60-69, 70-79 and ≥80 years. Complications at 30 days were stratified using the Clavien system. Functional outcomes were assessed using the International Prostate Symptom Score (IPSS), maximum urinary flow rate (Qmax), post-void residual urine volume (PVR) and urinary continence. Results A total of 311 patients underwent HoLEP for obstructive voiding symptoms from August 2007 to June 2011, of whom 22 patients were aged 50-59 years, 91 were aged 60-69 years, 153 were aged 70-79 years, and 45 were aged ≥80 years. The overall morbidity rates were similar among the age groups (20, 24.4, 21.6 and 22.1{\%} for groups 1, 2, 3 and 4, respectively), as were the incidence of significant complications (Clavien grade ≥ III), change in serum haemoglobin level, and length of hospital stay. Patients ≥80 years did have a longer catheterization time (3.4 days) than patients aged 50-59 years (1.68 days). By 1 year there were no significant differences in urinary continence, IPSS, Qmax, or PVR among the age groups. Conclusions Overall morbidity, hospital stay, and 1-year functional outcomes of HoLEP were similar among all age groups. This study shows that HoLEP is a safe and effective treatment for benign prostatic hyperplasia regardless of age.",
keywords = "BPH, enucleation, holmium, laser, prostate",
author = "Mmeje, {Chinedu O.} and Rafael Nunez-Nateras and Warner, {Jonathan N.} and Humphreys, {Mitchell R}",
year = "2013",
month = "11",
doi = "10.1111/bju.12063",
language = "English (US)",
volume = "112",
pages = "982--989",
journal = "BJU International",
issn = "1464-4096",
publisher = "Wiley-Blackwell",
number = "7",

}

TY - JOUR

T1 - Age-stratified outcomes of holmium laser enucleation of the prostate

AU - Mmeje, Chinedu O.

AU - Nunez-Nateras, Rafael

AU - Warner, Jonathan N.

AU - Humphreys, Mitchell R

PY - 2013/11

Y1 - 2013/11

N2 - Objective To present the first age-stratified assessment of outcomes after holmium laser enucleation of the prostate (HoLEP) for the treatment of lower urinary tract symptoms resulting from prostate enlargement. Patients and Methods We retrospectively analysed and compared the morbidity, and the peri-operative and functional outcomes of patients aged 50-59, 60-69, 70-79 and ≥80 years. Complications at 30 days were stratified using the Clavien system. Functional outcomes were assessed using the International Prostate Symptom Score (IPSS), maximum urinary flow rate (Qmax), post-void residual urine volume (PVR) and urinary continence. Results A total of 311 patients underwent HoLEP for obstructive voiding symptoms from August 2007 to June 2011, of whom 22 patients were aged 50-59 years, 91 were aged 60-69 years, 153 were aged 70-79 years, and 45 were aged ≥80 years. The overall morbidity rates were similar among the age groups (20, 24.4, 21.6 and 22.1% for groups 1, 2, 3 and 4, respectively), as were the incidence of significant complications (Clavien grade ≥ III), change in serum haemoglobin level, and length of hospital stay. Patients ≥80 years did have a longer catheterization time (3.4 days) than patients aged 50-59 years (1.68 days). By 1 year there were no significant differences in urinary continence, IPSS, Qmax, or PVR among the age groups. Conclusions Overall morbidity, hospital stay, and 1-year functional outcomes of HoLEP were similar among all age groups. This study shows that HoLEP is a safe and effective treatment for benign prostatic hyperplasia regardless of age.

AB - Objective To present the first age-stratified assessment of outcomes after holmium laser enucleation of the prostate (HoLEP) for the treatment of lower urinary tract symptoms resulting from prostate enlargement. Patients and Methods We retrospectively analysed and compared the morbidity, and the peri-operative and functional outcomes of patients aged 50-59, 60-69, 70-79 and ≥80 years. Complications at 30 days were stratified using the Clavien system. Functional outcomes were assessed using the International Prostate Symptom Score (IPSS), maximum urinary flow rate (Qmax), post-void residual urine volume (PVR) and urinary continence. Results A total of 311 patients underwent HoLEP for obstructive voiding symptoms from August 2007 to June 2011, of whom 22 patients were aged 50-59 years, 91 were aged 60-69 years, 153 were aged 70-79 years, and 45 were aged ≥80 years. The overall morbidity rates were similar among the age groups (20, 24.4, 21.6 and 22.1% for groups 1, 2, 3 and 4, respectively), as were the incidence of significant complications (Clavien grade ≥ III), change in serum haemoglobin level, and length of hospital stay. Patients ≥80 years did have a longer catheterization time (3.4 days) than patients aged 50-59 years (1.68 days). By 1 year there were no significant differences in urinary continence, IPSS, Qmax, or PVR among the age groups. Conclusions Overall morbidity, hospital stay, and 1-year functional outcomes of HoLEP were similar among all age groups. This study shows that HoLEP is a safe and effective treatment for benign prostatic hyperplasia regardless of age.

KW - BPH

KW - enucleation

KW - holmium

KW - laser

KW - prostate

UR - http://www.scopus.com/inward/record.url?scp=84886095243&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84886095243&partnerID=8YFLogxK

U2 - 10.1111/bju.12063

DO - 10.1111/bju.12063

M3 - Article

VL - 112

SP - 982

EP - 989

JO - BJU International

JF - BJU International

SN - 1464-4096

IS - 7

ER -